IP Library Granted Patent US 8,519,143
Granted Patent B2
US 8,519,143 · App. 13/473,885 · Granted Aug 27, 2013

Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors

Inventors: Marco Baroni (Milan, IT); Francoise Bono (Toulouse, FR); Sandrine Delbary-Gossart (Mauzac, FR)
Assignee: Sanofi
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,519,143
App. No.
13/473,885
Granted
Aug 27, 2013
Kind
B2
Abstract

The present invention relates to derivatives of ((phenyl)-3,6-dihydropyridin-1-yl)(bridged piperazinyl)-1-alkanone derivatives and ((phenyl)-2,5-dihydropyrrol-1-yl) (bridged piperazinyl)-1-alkanone corresponding to Formula (I): in which the variables are as defined herein, to the preparation thereof and to the therapeutic use thereof.

Claims (25)

1. A compound of Formula (II):

in which:

m represents 0 or 1;

A represents:

and B represents a hydrogen atom or

A represents a hydrogen atom and B represents:

n represents 1 or 2;

R1 represents a halogen atom, a (C 1 -C 4 )alkyl group, a trifluoromethyl group, a (C 1 -C 4 )alkoxy group or a trifluoromethoxy group;

R2 represents a hydrogen atom, a halogen atom, a (C 1 -C 4 )alkyl group, a trifluoromethyl group, a (C 1 -C 4 )alkoxy group, a trifluoromethoxy group, a COOR group or a CONH 2 group;

R represents a C 1 -C 6 alkyl group;

and Hal represents a halogen atom;

with the exception of 2-chloro-1-[4-(2-methoxyphenyl)-3,6-dihydro-2H-pyridin-1 -yl]ethanone and of 2-chloro-1-[4-(4-bromophenyl)-3,6-dihydro-2H-pyridin-1 -yl]ethanone;

in the form of a base or of a pharmaceutically acceptable addition salt with an acid.

2. A compound according to claim 1 , in which R2 is a hydrogen atom, a trifluoromethyl group, a COOR group or a CONH 2 group; in the form of a base or of a pharmaceutically acceptable addition salt with an acid.

3. A compound according to claim 1 , wherein:

m represents 1;

A represents:

and B represents a hydrogen atom;

n represents 1 or 2;

R1 represents a halogen atom, a (C 1 -C 4 )alkyl group, a trifluoromethyl radical, a (C 1 -C 4 )alkoxy group or a trifluoromethoxy radical; and

R2 represents a hydrogen atom, a halogen atom, a (C 1 -C 4 )alkyl group, a trifluoromethyl radical, a (C 1 -C 4 )alkoxy group or a trifluoromethoxy radical;

in the form of a base or of a pharmaceutically acceptable addition salt with an acid.

4. A compound according to claim 1 , wherein n=1;in the form of a base or of a pharmaceutically acceptable addition salt with an acid.

5. A compound according to claim 1 , wherein R1 is a halogen atom or a trifluoromethyl radical; in the form of a base or of a pharmaceutically acceptable addition salt with an acid.

6. A compound according to claim 1 , wherein R2 is a hydrogen atom or a trifluoromethyl radical; in the form of a base or of a pharmaceutically acceptable addition salt with an acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2013
From: BARONI, MARCO; BONO, FRANCOISE; DELBARY-GOSSART, SANDRINE
To: SANOFI-AVENTIS
Reel/Frame 029601/0930 →
CHANGE OF NAME Recorded Jan 10, 2013
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 029602/0102 →
Priority Claims (1)
FR 08 03299 · Jun 13, 2008 · national
Continuity (3)
Division 12966413 · Dec 13, 2010
Continuation PCTFR2009051118 · Jun 12, 2009
Related Publication 20120232280A1 · Sep 13, 2012